MedTrace Logo

Emapalumab Prevention of CAR-T Cell Associated Toxicities

NCT06550141 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-11-14

No results posted yet for this study

Summary

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).

The research study involves the following study interventions:

* Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
* Axicabtagene Ciloleucel
* Emapalumab

Conditions

Interventions

DRUG

Emapalumab

An interferon gamma (IFNγ) blocking antibody

DRUG

Cyclophosphamide

Alkylating agent

DRUG

Fludarabine Phosphate

Purine antagonist antimetabolite

DRUG

Axicabtagene Ciloleucel

Autologous treatment

Sponsors & Collaborators

  • Swedish Orphan Biovitrum

    collaborator INDUSTRY

  • Marcela V. Maus, M.D.,Ph.D.

    lead OTHER

Principal Investigators

  • Matthew Frigault, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-18
Primary Completion
2026-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06550141 on ClinicalTrials.gov